Skip to content

Phenotype and function of dendritic cells in different stages of allergic rhinitis

Phenotype and function of dendritic cells in different stages of allergic rhinitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016041
Enrollment
Unknown
Registered
2018-05-08
Start date
2018-05-10
Completion date
Unknown
Last updated
2018-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Case series:Nil

Sponsors

Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. not used glucocorticoid systemically in least month; 2. be diagnosed as nasal polyps according to Guidelines for diagnosis and treatment of allergic rhinitis (2015, Tianjin); 3. aged >= 18 years male and female; 4. voluntarily participate in the study, follow the study regulations, and voluntarily sign written informed consent; 5. male weight > 50kg, female weight > 40kg.

Exclusion criteria

Exclusion criteria: 1. pregnant or lactating women; 2. autoimmune diseases( e.g. lupus erythematosus, rheumatoid arthritis, systemic vasculitis, granulomatous disorder), tumor, hematological system diseases, coagulation disorders, immunodeficiency or organ transplantation history; 3. acute infectious disease, upper respiratory infection, or symptoms of systemic inflammation( e.g. fever, chills and so on); 4. serious metabolic, cardiovascular, immunological, neurological, hematological, digestive, cerebrovascular or respiratory diseases, or other diseases which may interfere with the study results or impact the safety of the participants; 5. currently participate in other clinical studies or staff who directly participate in this study; 6. psychiatric history, against character, unfavored motive, paranoid or other emotional and mental problems, which may impact the validity of informed consent.

Design outcomes

Primary

MeasureTime frame
blood routine examination;OBK713;

Countries

China

Contacts

Public ContactJian-Bo Shi

Otorhinolaryngology Hospital, The First Affiliated Hospital, Sun Yat-sen University

tsjbent@163.com+86 020-87333733

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026